engleski

Serum calprotectin: A circulating biomarker of the inflammatory state in Philadelphia-negative myeloproliferative neoplasms

This multicenter retrospective study investigated serum calprotectin levels in patients with essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). Serum calprotectin levels were higher in ET, PV, and MF patients when compared to healthy controls ; however, there was no difference in serum calprotectin levels between the three disorders. Higher serum calprotectin levels correlated with clinical and laboratory parameters indicative of a higher systemic inflammation. These results suggested that serum calprotectin may be a novel circulatory inflammatory biomarker in patients with myeloproliferative neoplasms.

serum calprotectin ; essential thrombocythemia ; polycythemia vera ; myelofibrosis

nije evidentirano